Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma.

Abstract

We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG). We calculated the difference between a patient's total serum protein and albumin as a point-of-care test for assessing disease status in MM. GG is highly correlated with the level of M-spike, and the change in GG correlates with myeloma treatment response. In addition, fitted linear models were established that allow for the calculation of M-protein level from the GG within hours from blood draw. Our study has important implications in the care of MM, particularly in countries/areas with limited resources.